Noveko Announces Firm Orders Worth $18 Million for its Antimicrobial Face Masks and AZURO(TM) Sanitizers

Noveko International Inc. ("the Company") is pleased to announce that the value of its firm orders for its Noveko(TM) antimicrobial face masks and respirators and AZURO(TM) hand sanitizers, for the period beginning July 1st, 2009, currently totals approximately $18 million, i.e. $12 million for face masks and respirators and $6 million for sanitizers. This significant number of orders reflects the sharp increase in demand for the Company's antimicrobial products. The orders come mainly from various distributors, notably Eval Consulting, BLD Distribution L.L.C., Aerosys Technologies and Medi-Select.

The Noveko(TM) antimicrobial face masks and respirators and AZURO(TM) hand sanitizers will be delivered over the coming months to different markets such as Canada, the United States, Mexico, South America, Europe, the Maghreb, the Middle East and Asia

Zargis Receives FDA Clearance for Signal X6 Telemedicine Device; OK Allows Delivery to US Army

Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced today it has received U.S. Food and Drug Administration (FDA) clearance to market its new Signal X6(TM) device. Zargis also announced the delivery of seven Signal X6 devices to the U.S. Army for deployment in six Department of Defense medical facilities.

Signal X6 is noninvasive, easy to use and simultaneously records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, for locations where a cardiac specialist is not immediately available for consultation, transmitted through the Internet for remote evaluation. Signal X6 and our recently launched Zargis Cardioscan(TM) device were both designed for user-friendly digital heart sound analysis.

Syneron Medical Ltd. and Candela Corporation to Merge Creating a Leading Global Aesthetic Device Company

Syneron Medical Ltd. (NASDAQ: ELOS) and Candela Corporation (NASDAQ: CLZR) announced today that they have entered into a definitive agreement to combine the companies in an all stock transaction. This strategic combination, unanimously approved by the Boards of Directors of both companies, will create a global leader in medical aesthetic devices. The transaction is expected to be completed by year-end 2009.

Under the terms of the merger agreement, Candela shareholders will receive 0.2911 ordinary shares of Syneron for each share of Candela common stock they own. Based upon the closing stock price of Syneron common stock on September 8, 2009, this represents $2.84 per share of consideration to be received by Candela shareholders, or a total consideration of approximately $65 million.

IMRIS receives FDA clearance for IMRISNV and IMRIScardio

IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA), permitting the Company to market its newest products, IMRISNV and IMRIScardio in the United States.

IMRISNV and IMRIScardio are the first systems in the world to allow the capabilities of both MRI and x-ray angiography in a single suite without the need to transport the patient between modalities.

Neurovascular diseases including acute ischemic stroke require rapid assessment and treatment. IMRISNV features a wide bore 3T MRI scanner and a bi-plane angiography system completely integrated into a single suite that permits the patient to transition quickly and seamlessly between MR imaging and intervention without transporting the patient between modalities.